Ticker LaunchIPO · LGVN
Longeveron Inc.
Formerly LONGEVERON LLC
Longeveron Inc. (LGVN) priced its initial public offering on Feb 12, 2021 at $10.00 per share, within its $10.00–$12.00 range, raising $26.6M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $187.1M. Kingswood was lead-left underwriter, joined by Benchmark. Nelson Mullins advised the underwriters.
Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead product, Lomecel-B, is derived from medicinal signaling cells from young donors' bone marrow and is in Phase 1 and 2 trials for aging frailty, Alzheimer's disease and other conditions.
- Status
- IPO
- Ticker
- LGVN
- Exchange
- Nasdaq Capital Market
- Priced
- Feb 12, 2021
- IPO price
- $10.00
- Price range
- $10.00–$12.00
- Raised
- $26.6M
- Market cap at IPO price
- $187.1M
- First filed
- Jan 19, 2021
- Underwriters' counsel
- Nelson Mullins
- Sector
- Biotech & pharma
- Country / state
- FL
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 19, 2021
- Latest amendment Feb 10, 2021
- Final prospectus (424B4) Feb 12, 2021
- All filings on EDGAR CIK 1721484
Other Biotech & pharma IPOs in 2021
- Decibel Therapeutics, Inc.DBTX · Feb 12, 2021 · $127.1M
- Biophytis SABPTS · Feb 11, 2021 · $20.1M
- GRI Bio, Inc.VLON · Feb 11, 2021 · $18M
- Adagene Inc.ADAG · Feb 10, 2021
- Immunocore Holdings plcIMCR · Feb 8, 2021
- Lucira Health, Inc.LHDX · Feb 8, 2021 · $153M